CS Paper Radar

AI-assisted mitotic counting improves reproducibility and efficiency across multiple tumour types

Simon Graham, Mostafa Jahanifar, Quoc Dang Vu, Vygante Maskoliunaite, Donatas Petroska, Ruta Barbora Valkiuniene, Ayat Gamal Lashen, Jen Hong Ong, Amede Ogechi Nnorom, Sinclair Couper, Natasha Kardasz, Reshma Agrawal, Brinder Singh Chohan, Jose Luis Solorzano Rendon, Shonali Natu, Arvydas Laurinavicius, Nasir Rajpoot, David Snead

cs.AI ·submitted 2026-10-01 14:48 UTC · v1

Abstract

Mitotic counting is an important component of tumour grading, diagnosis and prognostic assessment across several tumour types, but manual assessment is time-consuming and subject to inter-pathologist variability. To help address these challenges, we developed MitPro, an AI tool designed to improve consistency and efficiency by directing pathologists towards regions with the highest predicted mitotic activity and highlighting mitotic figures for review, while retaining pathologist control over region selection and the final count. We evaluated its effect on the reproducibility and efficiency of mitotic counting in a retrospective, non-interventional, paired reader study comprising 385 whole-slide images from 3 centres in 3 countries and 7 tumour types using 3 different scanners. 13 pathologists participated, with each slide assessed independently by 3 pathologists without AI assistance and again with AI assistance after a minimum 2 week washout period. Across all slides, AI-assisted counting increased the intraclass correlation coefficient from 0.589 to 0.949. Mean pathologist-level median assessment time decreased from 286.4 to 127.8 seconds, corresponding to an average saving of 151.8 seconds per assessment. Improvements in agreement and efficiency were also observed in supporting analyses using HALO AP and Sectra image management systems and in 2 additional tumour types outside the main study population. AI-assisted assessment was associated with a subtle shift towards higher mitotic counts and scores, consistent with identification of more active mitotic hotspots and fewer missed mitotic figures. The frequency of score change between unassisted and AI-assisted assessment was comparable with inter-pathologist variation during routine counting. These findings support the use of MitPro as an assistive tool for more consistent and efficient mitotic assessment in routine practice.

Closest papers

Nearest neighbours by meaning across the whole index.

Automated PD-L1 Tumor Proportion Scoring with Uncertainty-Guided Triage in Non-Small Cell Lung Cancer

cs.CV eess.IV ·2026-11-12 ·Kesi Xu, Ayesha Azam, Tanvier Kaur, Monika Kondratowicz, Kinza Asim +5 more
hot direction similarity 0.66
Abstract · 55 pages (29-page main text with 5 figures and 3 tables, followed by 26 pages of supplementary material)

Programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) informs immunotherapy selection in non-small cell lung cancer. Near the 1% and 50% cutoffs, the score should also indicate when closer review is warranted. We designed a three-stage framework to follow the sequence of TPS assessment. Stage 1 identifies tumor regions and excludes macrophage-rich patches. Stage 2, a dual-branch cell counting network (D2Count-Net), counts PD-L1-positive and PD-L1-negative tumor cells in these regions to calculate TPS. Stage 3, TPS-Guard, an uncertainty-guided triage mechanism, reports model uncertainty as the disagreement among independently trained models, refers the most uncertain slides, and flags scores near the 1% or 50% cutoff when model estimates disagree across that cutoff. Flags state the reason for referral or alert the pathologist to possible scoring errors on auto-reported slides. In a retrospective, single-center study, 154 whole-slide images were scored by three pathologists, and the model and each pathologist were compared in turn with the mean of the other two. On the 114 slides unseen in training, model mean absolute error (MAE) was 6.96 percentage points, within the range of the three pathologists (4.24 to 8.29), and model uncertainty correlated with absolute TPS error (Spearman rho = 0.77) and inter-pathologist disagreement (rho = 0.71). After referral of the 15% most uncertain slides, model and pathologist MAE both decreased. Applied without retraining to an external, publicly available dataset, TPS-Guard still directed review to higher-error cases, and referring more uncertain cases raised sensitivity at the 50% cutoff. TPS-Guard provides reasons for reviewing individual automated scores and identifies slides that also produce greater disagreement among pathologists. Prospective reader studies should assess TPS-Guard's effect on TPS reporting.

0.32

PathCowork: Learning from real-world pathology practice to build AI copilots

cs.CV ·2026-10-29 ·Sheng Wang, Jialu Yao, Maria V. Rossi, Shunsuke Koga, Esther Baranov +20 more
code/data similarity 0.64
Abstract · 56 pages, including supplementary information. Code, models and demonstration videos: https://github.com/zhihuanglab/PathCowork

Medical AI learns from the answers doctors record, but rarely from how they interpret the evidence to reach them. Here we introduce PathCowork, a framework that turns pathologists' narrated examinations into supervision for visual grounding and procedures that guide diagnostic AI agents. Synchronized gaze, narration and navigation link visual findings to the process of interpreting them. Across 48 sessions from 16 pathologists, the platform captured 1,028 minutes of slide review. Using these data, we trained PathCowork-1T for server deployment and PathCowork-27B for local deployment, with improved visual grounding. Across five organ-specific evaluations, agents combining this grounding with recorded diagnostic procedures achieved primary task scores averaging 17.9 and 24.1 percentage points higher than Claude Code and Codex, respectively, with shorter processing times and lower inference costs. Compared to the state-of-the-art multiple-instance learning AIs, the PathCowork agent-proposed regions achieved higher prostate-grading scores with limited slide labels. PathCowork can also help construct pathology AI benchmarks where questions derived from the recordings identified difficulties in recognizing viewing context and rejecting inapplicable premises. In summary, PathCowork proposes a new paradigm to scale up the data collection and train pathology AI through transparent reasoning from diagnostic sessions, opening a path towards systems that learn directly from routine clinical practice.

0.26

PRET is a few-shot system for pan-cancer recognition without example training

cs.CV ·2026-10-18 ·Yi Li, Ziyu Ning, Tianqi Xiang, Qixiang Zhang, Zhihao Lin +15 more
publishedhighly cited similarity 0.61
Abstract · Nature Cancer Accepted

Pathological examination stands as the cornerstone in cancer diagnosis, impacting millions worldwide annually. With the shortage of pathologists globally, artificial intelligence (AI) has emerged rapidly to automate the diagnostics process. However, conventional AI models require substantial labeled data for each disease, posing huge challenges in scalability and practicality. Therefore, we introduce PRET (pan-cancer recognition without examples training), a few-shot system to achieve flexible, scalable, and effective cancer recognition across diverse organs, hospitals and tasks without training. Evaluated on 23 international benchmarks comprising 4,484 whole-slide images, our method outperforms existing approaches across 20 tasks, achieving over 97% area under the curve on 15 benchmarks with a maximum improvement of 36.76%. Notably, PRET delivers clinical-grade diagnostic performance in lymph node metastasis detection using only eight slide examples, outperforming 11 pathologists. By offering a flexible and cost-effective solution for pan-cancer recognition, PRET paves the way for accessible and equitable AI-based pathology systems, particularly benefiting minority populations and underserved regions.

0.46

PathPilot: An Adaptive Question-Conditioned Multi-Magnification Navigation Agent for Whole-Slide Image Analysis

cs.CV ·2026-10-12 ·Zhengyang Xu, Han Li, Jingsong Liu, Ayako Ura, Shihui Zu +3 more
similarity 0.59
Abstract

The diagnostic capability of WSI agents relies on effective slide navigation to identify diagnostically relevant regions and efficiently integrate evidence across the slide. While in clinical practice, pathologists dynamically examine slides across multiple scales, integrating global and cellular evidence in a sequential manner, existing AI navigation approaches mostly operate at a single fixed magnification or rely on predefined magnification traversal. This mismatch prevents existing methods from modeling cross-magnification interactions and adaptive magnification selection inherent to real diagnostic workflows. We propose PathPilot, a clinically consistent multi-magnification WSI navigation agent that explicitly models cross-magnification localization and evidence-adaptive exploration. Specifically, we introduce a CrossMagLoc that learns magnification-specific diagnostic localization from pathologist viewing behavior and integrates information from adjacent magnifications to identify the diagnostically most relevant region within the current ROI, thereby providing a diagnostically informed starting point for subsequent question-conditioned exploration. We further introduce an EviRegionSearch that starts question-conditioned exploration from this region, progressively accumulating question-relevant evidence and adaptively determining the next navigation action according to the remaining evidence requirement. Their iterative interaction enables PathPilot to sequentially explore across ROIs and magnifications until sufficient evidence is acquired. Extensive QA evaluations across five cohorts demonstrate consistent superiority over competing SOTA methods on inter/external cohorts, respectively, validating question-conditioned evidence acquisition across regions and magnifications that mirrors the sequential, knowledge-driven navigation of pathologists.

0.34

Multimodal Fusion Methods for Whole-Slide Images and Clinical Data in Inflammatory Bowel Disease

cs.CV cs.AIcs.LG ·2026-11-03 ·Ankana Banerjee, Mark van der Giezen, Ole Gunnar Aasprong, Emiel A. M. Janssen, Øyvind Steinsbø +2 more
similarity 0.59
Abstract · 5 pages, 4 figures, Submitted to the 2027 IEEE 24th International Symposium on Biomedical Imaging (ISBI)

Multimodal AI fusion of histology and clinical data is an active research area in computational pathology, but fusion methods are rarely compared under identical conditions and across different clinical endpoints. We present a modular framework in which slide-level embeddings, obtained by training an attention-based aggregator over patch embeddings from a frozen foundation model, and per-visit clinical embeddings are fed into 15 interchangeable fusion methods with a shared output dimension and prediction head (except decision-level methods). Using a prospective cohort of newly diagnosed inflammatory bowel disease patients, we predicted STRIDE-II-aligned remission outcomes from baseline or follow-up visits. The best fusion method reached macro-F1 of 0.57-0.75, outperforming both single-modality models in four of six scenarios, and differed by outcome and input. Image reliance, the drop in balanced accuracy when the slide embedding is removed, tended to follow the remission type - highest for histological and lowest for endoscopic remission; methods with similar accuracy relied on the slide to very different degrees.

0.24

SCOUT: Risk-Guided Foundation-Model Escalation for Robust Tissue Detection in Whole-Slide Images

cs.CV ·2026-11-18 ·Cristian Tommasino, Antonio M. Rinaldi
benchmarkcode/data similarity 0.58
Abstract

Reliable tissue detection is essential for whole-slide image analysis, yet high average segmentation accuracy can conceal failures involving pale tissue, small fragments, and heterogeneous staining. Pathology foundation models offer transferable representations, but exhaustive inference is computationally demanding and may introduce false-positive tissue predictions. We propose SCOUT (Selective Correction of Uncertain Tissue), a risk-guided cascade that selectively refines an initial thumbnail-based tissue mask. A lightweight audit network estimates the spatial distribution of segmentation errors and prioritizes candidate regions for processing by a frozen pathology foundation model. An asymmetric consensus rule integrates the resulting predictions with the initial mask to recover missed tissue while limiting false positives. A calibrated slide-level review score additionally controls the marginal rate of unflagged case-group failures under the calibration assumptions. Evaluation on a public multi-source, multi-stain benchmark shows that SCOUT reduces the proportion of case groups requiring mask correction from 38.1% for the best released detector to 18.6%, with particularly pronounced improvements in immunohistochemistry. Source-held-out experiments demonstrate better generalization than a segmentation network trained on the same annotations, while selective inference achieves an observed failure rate no higher than processing all candidate regions. Downstream, lymph-node classification with SCOUT masks is non-inferior to that obtained with two of the three released detectors evaluated. A variant built on an openly licensed foundation model is publicly released as an installable Python package with trained weights. These results support risk-guided foundation-model inference as an effective approach to tissue detection across heterogeneous histopathology data.

0.28

MiTHras: Task-specific Hierarchical Semi-supervised Contrastive Masked Autoencoder for Mitotic Figure Analysis

cs.CV cs.LG ·2026-09-21 ·Trinh T. L. Vuong, Simon Graham, Quoc Dang Vu, Phat T. H. Ho, Jeewoo Lim +3 more
published similarity 0.58
Abstract · 15 pages, 4 figures, 9 tables. Includes supplementary material

Mitotic figure (MF) analysis supports tumor grading and prognostic assessment, but automated models remain sensitive to differences in tissue type and image acquisition. We present MiTHras, a task-specific pretraining framework that combines pseudo-label-guided image- and token-level contrastive learning with masked reconstruction. We construct TCGA-MF-Pseudo, a corpus of 1.8 million cell-centered images from 14 TCGA cohorts spanning 11 organ sites. Comprehensive evaluation on MF classification, detection, count-based survival prediction, and subtype classification demonstrates the efficacy of MiTHras. It achieves the highest mean F1 on all three MF classification benchmarks and both subtype benchmarks. MiTHras also outperforms general-purpose and pathology foundation encoders by a larger margin under frozen-encoder linear probing than under full fine-tuning. Although detection gains are modest due to a shared candidate-detection stage, ablations confirm that token-level supervision improves typical-versus-atypical classification and linear probing. These findings establish that MiTHras yields robust, transferable representations for automated mitotic activity assessment.

0.43

A Vision-Language Foundation Model for Precise and Comprehensive Brain Tumor Diagnosis from Preoperative Multimodal Data

cs.CV cs.AI ·2026-09-15 ·Yinong Wang, Jianwen Chen, Zhou Chen, Shuwen Kuang, Haoning Jiang +26 more
code/data similarity 0.57
Abstract · 94 pages, 22 Figures, supplement files, Project page link: https://hku-healthai.github.io/brainvlm_project.github.io/

We developed BrainVLM to classify all 12 World Health Organization (WHO) 2021 brain tumor types. BrainVLM integrates an uncertainty quantification strategy to indicate prediction reliability and a module for generating radiology reports to elucidate the clinical rationale. BrainVLM was trained on multi-modal data (MRI scans, demographics, and radiology reports) from 40,043 individuals. It was validated on 5,211 patients with pathologically confirmed brain tumors, including 3,877 held-out patients from the primary hospital and 1,334 patients from 11 independent hospitals. We further conducted two proof-of-concept studies to validate its clinical utility in AI-clinician workflows: 1) a blinded multireader study where 12 neuroradiologists across varying experience levels interpreted 248 retrospective cases with or without AI assistance, and 2) a real-world prospective study in which 1,009 patients were independently and blindly assessed by BrainVLM and radiologists before surgery. Additionally, we demonstrated BrainVLM's utility in preoperative molecular subgroup prediction for adult-type diffuse gliomas, using a multi-center cohort of 632 patients. In primary evaluation, BrainVLM achieved an area under the curve (macro-AUC) of 0.85 (95% CI: 0.84-0.86), and an F1 score of 0.82 (95% CI: 0.81-0.83), surpassing neuroradiologists (F1 = 0.80 (95% CI: 0.79-0.81)). In external validation across 11 centers, BrainVLM achieved an AUC = 0.80 (95% CI: 0.79-0.82) and F1 = 0.75 (95% CI: 0.73-0.78), compared with F1 = 0.71 (95% CI: 0.69-0.73) for neuroradiologists. In prospective real-world evaluation, BrainVLM maintained performance comparable to neuroradiologists. The BrainVLM project page is available at https://hku-healthai.github.io/brainvlm_project.github.io/.

0.35